March 8, 2018 / 9:41 PM / 9 months ago

BRIEF-Oncocyte Announces Initial Results Of Determavu™ Feasibility On New Platforms

March 8 (Reuters) - Oncocyte Corp:

* ONCOCYTE ANNOUNCES INITIAL RESULTS OF DETERMAVU™ FEASIBILITY ON NEW PLATFORMS; ENHANCEMENTS MAY INCREASE LUNG CANCER DIAGNOSTIC TEST’S CLINICAL PERFORMANCE

* ONCOCYTE CORP - CO IS ACTIVELY EVALUATING ALTERNATIVE ASSAY PLATFORMS FOR USE WITH MOLECULAR BIOLOGY DIAGNOSTIC TESTING​

* ONCOCYTE CORP - ‍INITIAL RESULTS SHOW ILLUMINA PLATFORM COULD PROVIDE SUPPORT FOR CLINICAL DEVELOPMENT STUDIES NECESSARY FOR DETERMAVU​ COMMERCIALIZATION

* ONCOCYTE CORP - ‍ONCOCYTE HAS ALSO IDENTIFIED WAYS THAT POTENTIALLY MAY ENHANCE LUNG CANCER SIGNAL IDENTIFIED BY DETERMAVU​

* ONCOCYTE - CO EXTENDING EVALUATION OF COMMERCIAL MOLECULAR DIAGNOSTIC PLATFORMS BY DOING A FOLLOW-ON STUDY UTILIZING LARGER SET OF CLINICAL SAMPLES​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below